Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 tumor suppressor is vital for preventing cancer.
• MDM2 and MDMX proteins regulate p53 stability and activity.
• Inhibiting both MDM2 and MDMX is crucial for effective p53 activation in some tumors, but current inhibitors like Nutlin are insufficient against MDMX.

Purpose of the Study:

• To investigate the feasibility and biological impact of simultaneously blocking p53 interactions with MDM2 and MDMX.
• To identify novel therapeutic strategies for cancers with MDM2 and MDMX overexpression.

Main Methods:

• Phage display was used to discover a peptide targeting p53-MDM2 and p53-MDMX interactions.
• Adenovirus expressing a thioredoxin-displayed peptide was constructed.
• The efficacy of the peptide was assessed in tumor cells and xenograft models.

Main Results:

• A novel peptide was identified with high affinity for inhibiting p53 binding to MDM2 (IC50 = 10 nmol/L) and MDMX (IC50 = 100 nmol/L).
• Adenovirus-mediated expression of the peptide disrupted p53-MDM2/MDMX interactions, inducing p53 activation, cell cycle arrest, and apoptosis in tumor cells.
• Intratumoral administration of the adenovirus suppressed tumor xenograft growth in mice via a p53-dependent mechanism.

Conclusions:

• Simultaneously targeting MDM2 and MDMX offers a promising therapeutic strategy for cancer treatment.
• The identified peptide represents a novel structural motif for developing potent p53 activators.
• This dual-inhibition approach holds potential for overcoming resistance associated with MDMX overexpression.